CMP Pharma Announces FDA-Approval on Atorvastatin Liquid Suspension

Published on: 

Atorvaliq indicated for the treatment of high cholesterol.

CMP Pharma, Inc. revealed that the FDA has officially approved Atorvaliq (atorvastatin calcium), and is now available. Manufactured for the treatment of high cholesterol and a number of risk factors for heart disease and stroke, the medication is a liquid oral suspension approved for patients 10 years of age and older.


"Atorvaliq is intended for a subset of the patient population that needs atorvastatin but has dysphagia or difficulty swallowing tablets. The availability of Atorvaliq gives healthcare providers and appropriate patients a convenient, safe, and FDA-approved liquid formulation," said Gerald Sakowski, CEO of CMP Pharma, Inc.

Reference: CMP Pharma, Inc Announces that Atorvaliq®, the First and Only FDA-approved Liquid Suspension of Atorvastatin is Now Available. PR Newswire. June 23, 2023. Accessed June 26, 2023.